Positive Trial Results For StemCells
Posted on February 12, 2013 at 16:13 PM EST
StemCells Inc. (Nasdaq: STEM) reported positive results from a Phase I/II clinical trial of its purified human neural stem cells product to treat chronic spinal cord injury. Shares of the biopharmaceutical climbed 35 cents to close at $1.99.
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here